Life sciences venture capital firm Medicxi has founded and announced the launch of Alys Pharma with $100m in seed financing. Based in Boston and Geneva, the biotech company aims to harness the immune system to treat various skin conditions.
Join our network of executives who receive the MBS News daily, as well as the insights, analysis and our weekly column in The Weekend Edition.
You’ll be able to unsubscribe at any time.